Aim and Objective: Alcohol is leading cause for liver disease and is associated with morbidity and mortality. Several factors including the amount and duration of alcohol consumption affect the development and progression of alcoholic disorder. Alcoholic hepatitis is a devastating acute form of alcoholic liver disease (ADL). Prednisone for alcoholic liver disease is an effective medication and it improves short term survival in patients. Background: Alcoholic hepatitis is a clinical syndrome characterised by jaundice and liver impairment that occurs in patients with a history of heavy and prolonged alcohol consumption. The short-term mortality among patients with severe disease exceeds 30%. Prednisolone and pentoxifylline are both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit persists. Result: Prednisolone was associated with a reduction in 28-day mortality that did not reach significance and with no improvement in outcomes at 90 days or 1 year. Prednisolone Reduced mortality, improved risk-benefit. Treatment with Prednisolone improves the short term survival of patients with severe biopsy proved alcoholic hepatitis.
Cite this article:
S. Thaminee. Prednisolone in Alcoholic Liver Disorder. Research J. Pharm. and Tech 2016; 9(11):2041-2042. doi: 10.5958/0974-360X.2016.00417.0
S. Thaminee. Prednisolone in Alcoholic Liver Disorder. Research J. Pharm. and Tech 2016; 9(11):2041-2042. doi: 10.5958/0974-360X.2016.00417.0 Available on: https://rjptonline.org/AbstractView.aspx?PID=2016-9-11-46